GlassScriptPhysician profile
Krishna H Suthar
NPI 1629504550
$1,115.72
in general payments reported to CMS, 2019-2025
8 companies · $62.96 in 2025
The $62.96 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2023: $602 · 2024: $255 · 2025: $62.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $681 · Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $681.40 |
| Food and Beverage | $238.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $450.82 | 2021-2024 | Retevmo, Jaypirca |
| Astellas Pharma US INC | $326.94 | 2021-2024 | |
| Janssen Biotech, INC. | $124.70 | 2023 | Carvykti, Darzalex, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $99.00 | 2023 | |
| Stemline Therapeutics INC. | $51.30 | 2023 | Orserdu |
| Puma Biotechnology, INC. | $26.07 | 2025 | |
| Genmab U.S., INC. | $20.89 | 2025 | Epkinly |
| Eisai INC. | $16.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Suthar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.